GlassScriptPhysician profile
Thomas W Ferguson
NPI 1831292309
$6,161.60
in general payments reported to CMS, 2019-2025
27 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $334 · 2021: $409 · 2022: $981 · 2023: $2,273 · 2024: $658 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205 · Honoraria: $1,400 · Education: $49.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.18 |
| Honoraria | $1,400.00 |
| Education | $49.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,593.88 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Horizon Therapeutics Plc | $1,566.98 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $442.72 | 2019-2025 | Jynarque |
| Amgen INC. | $427.52 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $320.44 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $256.94 | 2019-2021 | |
| Travere Therapeutics, INC. | $188.88 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $184.58 | 2022-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $158.86 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $125.75 | 2021-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $119.93 | 2022-2025 | Lupkynis |
| Gilead Sciences, INC. | $119.59 | 2019 | |
| Nxstage Medical, INC. | $91.85 | 2019-2023 | Nxstage System One, Liberty Select Cycler |
| Bayer Healthcare Pharmaceuticals INC. | $91.29 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $81.19 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $77.04 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $76.29 | 2022-2025 | Tarpeyo |
| Genzyme Corporation | $46.94 | 2019 | |
| Daiichi Sankyo INC. | $46.49 | 2019-2022 | |
| Shire North American Group INC | $25.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.82 | 2024 | Crysvita |
| Astellas Pharma US INC | $20.36 | 2025 | Izervay |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.53 | 2019 | |
| Genentech USA, INC. | $16.97 | 2019 | |
| Avion Pharmaceuticals | $12.09 | 2020 | |
| Xeris Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.